Nab-paclitaxel plus gemcitabine <i>vs.</i> gemcitabine for metastatic pancreatic cancer in China: a health economic evaluation_Chinese Journal of Evidence-Based Medicine

Authors：

WANG Yaling ¹ ,  DING Ningxin ² , LI Wenxiong ³

1. Affiliated Fuyang Hospital of Anhui Medical University, Fuyang, 236000, P.R.China;
2. PHARMAC, Wellington, 006012, New Zealand;
3. Beijing Chao-Yang Hospital, Beijing, 100043, P.R.China;

Corresponding author：

DING Ningxin, Email: cynical_ding@live.cn

Keywords：

Metastatic pancreatic cancer; Nab-paclitaxel; Gemcitabine; Cost-effectiveness; Markov model; Cost-utility analysis

DOI：

10.7507/1672-2531.201901013

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objectives To evaluate the economic efficacy of nab-paclitaxel (NAB-P) combined with gemcitabine (GEM) versus GEM alone in the treatment of metastatic pancreatic cancer in China.Methods A Markov model simulating the costs and health outcomes was developed to estimate quality-adjusted life years (QALYs) and incremental cost-effectiveness ratio (ICER). The impact of parameter uncertainty on the model was assessed by deterministic one-way sensitivity analysis.Results NAB-P combined with GEM was shown superior efficacy compared to gemcitabine monotherapy, however with higher costs. The ICER between the two groups was 964 780.79￥/QALY.Conclusions Compared with gemcitabine monotherapy, NAB-P combined with GEM is not cost-effective. The conclusion is confirmed by deterministic one-way sensitivity analysis.

Citation： WANG Yaling, DING Ningxin, LI Wenxiong. Nab-paclitaxel plus gemcitabine vs. gemcitabine for metastatic pancreatic cancer in China: a health economic evaluation. Chinese Journal of Evidence-Based Medicine, 2019, 19(9): 1101-1105. doi: 10.7507/1672-2531.201901013 Copy

1.	王付湘. 吉西他滨单药与吉西他滨联合化疗治疗晚期胰腺癌疗效及安全性评价. 中外医学研究, 2015, (14): 145-147.
2.	杨军, 李贺, 郑荣寿, 等. 2014 年中国胰腺癌发病与死亡分析. 中国肿瘤, 2018, 27(6): 420-425.
3.	汤少梁, 陈文静. 基于 Markov 模型对我国晚期胰腺癌 3 种化疗方案的药物经济学研究. 中国药房, 2018, 29(6): 784-789.
4.	Burris HA 3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol, 1997, 15(6): 2403-2413.
5.	von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med, 2013, 369(18): 1691-1703.
6.	Gharaibeh M, McBride A, Bootman JL, et al. Economic evaluation for the UK of nab-paclitaxel plus gemcitabine in the treatment of metastatic pancreas cancer. Br J Cancer, 2015, 112(8): 1301-1305.
7.	Gharaibeh M, McBride A, Bootman JL, et al. Economic evaluation for the US of nab-paclitaxel plus gemcitabine versus FOLFIRINOX versus gemcitabine in the treatment of metastatic pancreas cancer. J Med Econ, 2017, 20(4): 345-352.
8.	陈菊香, 周红轩, 马兰, 等. 吉西他滨联合奥沙利铂或替吉奥对比吉西他滨单药治疗晚期胰腺癌临床观察. 安徽医药, 2015, (2): 359-362.
9.	王晓玥, 伍春燕, 宋秋, 等. 诊断相关分组医疗费用结算模式在中国的应用前景与探讨. 中国基层医药, 2013, 20(15): 2386-2387.
10.	姚岚. 医疗保障学. 北京: 人民卫生出版社, 2013.
11.	Tam VC, Ko YJ, Mittmann N, et al. Cost-effectiveness of systemic therapies for metastatic pancreatic cancer. Curr Oncol, 2013, 20(2): e90-e106.
12.	Goldstein D, El-Maraghi RH, Hammel P, et al. nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase Ⅲ trial. J Natl Cancer Inst, 2015, 107(2): 413.
13.	魏蕾, 李自雄, 秦叔逵, 等. 吉西他滨单药或联合白蛋白结合型紫杉醇治疗东亚人群晚期胰腺癌临床疗效的荟萃分析. 临床肿瘤学杂志, 2019, 24(2): 137-144.
14.	Gourgou-Bourgade S, Bascoul-Mollevi C, Desseigne F, et al. Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4/ACCORD 11 randomized trial. J Clin Oncol, 2013, 31(1): 23-29.
15.	Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med, 2011, 364(19): 1817-1825.

1. 王付湘. 吉西他滨单药与吉西他滨联合化疗治疗晚期胰腺癌疗效及安全性评价. 中外医学研究, 2015, (14): 145-147.
2. 杨军, 李贺, 郑荣寿, 等. 2014 年中国胰腺癌发病与死亡分析. 中国肿瘤, 2018, 27(6): 420-425.
3. 汤少梁, 陈文静. 基于 Markov 模型对我国晚期胰腺癌 3 种化疗方案的药物经济学研究. 中国药房, 2018, 29(6): 784-789.
4. Burris HA 3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol, 1997, 15(6): 2403-2413.
5. von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med, 2013, 369(18): 1691-1703.
6. Gharaibeh M, McBride A, Bootman JL, et al. Economic evaluation for the UK of nab-paclitaxel plus gemcitabine in the treatment of metastatic pancreas cancer. Br J Cancer, 2015, 112(8): 1301-1305.
7. Gharaibeh M, McBride A, Bootman JL, et al. Economic evaluation for the US of nab-paclitaxel plus gemcitabine versus FOLFIRINOX versus gemcitabine in the treatment of metastatic pancreas cancer. J Med Econ, 2017, 20(4): 345-352.
8. 陈菊香, 周红轩, 马兰, 等. 吉西他滨联合奥沙利铂或替吉奥对比吉西他滨单药治疗晚期胰腺癌临床观察. 安徽医药, 2015, (2): 359-362.
9. 王晓玥, 伍春燕, 宋秋, 等. 诊断相关分组医疗费用结算模式在中国的应用前景与探讨. 中国基层医药, 2013, 20(15): 2386-2387.
10. 姚岚. 医疗保障学. 北京: 人民卫生出版社, 2013.
11. Tam VC, Ko YJ, Mittmann N, et al. Cost-effectiveness of systemic therapies for metastatic pancreatic cancer. Curr Oncol, 2013, 20(2): e90-e106.
12. Goldstein D, El-Maraghi RH, Hammel P, et al. nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase Ⅲ trial. J Natl Cancer Inst, 2015, 107(2): 413.
13. 魏蕾, 李自雄, 秦叔逵, 等. 吉西他滨单药或联合白蛋白结合型紫杉醇治疗东亚人群晚期胰腺癌临床疗效的荟萃分析. 临床肿瘤学杂志, 2019, 24(2): 137-144.
14. Gourgou-Bourgade S, Bascoul-Mollevi C, Desseigne F, et al. Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4/ACCORD 11 randomized trial. J Clin Oncol, 2013, 31(1): 23-29.
15. Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med, 2011, 364(19): 1817-1825.

Previous Article
Delirium risk prediction models in intensive care unit patients: a systematic review
Next Article
Quality assessment of pediatric tuina systematic reviews/meta-analyses

Chinese Journal of Evidence-Based Medicine

Nab-paclitaxel plus gemcitabine vs. gemcitabine for metastatic pancreatic cancer in China: a health economic evaluation

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content